Alcon receives FDA approval for Triesence

Alcon Laboratories has announced that the US Food and Drug Administration has approved its Triesence injectable triamcinolone suspension for use in eye surgery.

The regulatory board approved the 40mg/ml suspension for visualisation during vitrectomy and for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Vitrectomy is a type of eye surgery in which some or all of the vitreous humor is removed from the eye and is often performed in patients with diabetic retinopathy, a detached retina, a macular hole or other conditions.

Triesence assists retinal surgeons with visualisation during this type of surgery.

While the active ingredient of Triesence – triamcinolone acetonide – has been used for many years to treat retinal disease, Alcon has stated that this new approval brings ophthalmologists a sterile, preservative-free formulation specifically developed for use in the eye to treat various retinal inflammatory conditions.

Uveitis is common form of eye inflammation also treatable with Triesence and is a condition where the uveal tract of the eye becomes inflamed.

Earlier this year, Alcon announced that it would expand its operations in Switzerland, with Fribourg becoming the central location for its administrative operations worldwide.